EGFR Pathway Modulation in Ductal Carcinoma in Situ of the Breast
Abstract
We proposed a clinical trial to study the modulation of the EGFR pathway in DCIS. Eligible patients have either a mammogram highly suspicious for DCIS or a recent diagnosis of DCIS through a core biopsy. Subsequently, patients whose DCIS expresses EGFR are randomized to receive an EGFR inhibitor (Iressa) or placebo for 3 weeks prior to surgery. The protocol was generated, approved by the IRB and an efficient system for specimen collection was implemented. Since EGFR expression was a crucial requirement to enter the study we developed the immunohistochemical assay for the detection of the EGFR and P-EGFR proteins. We conducted an IRB- approved, retrospective study of DCIS cases diagnosed by core biopsy at our institution. A total of 42 cases were studied for EGFR and P-EGFR. We showed that EGFR expression is present in 18.6% of DCIS and correlates with high grade. P-EGFR expression was low at 7%. We also conducted a retrospective study using paraffin embedded tissues. 50 cases of DCIS were obtained from the Cooperative Breast Cancer Tissue Resource (CBCTR). IHC studies were performed for EGFR, P-EGFR, Ki67, p27, P-ERK, P-AKT. We confirmed that the rate of EGFR positivity in DCIS is 20%. P-EGFR expression was 5%.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2004
- Accession Number
- ADA428195
Entities
People
- Christina I. Truica
Organizations
- Vanderbilt University